Food-grade mulberry powder enriched with 1- deoxynojirimycin
suppresses the elevation of postprandial blood glucose in humans.
For SRT, N-butyl deoxynojirimycin
(Zavesca[R]) is approved as an inhibitor of glucosylceramide syntheses enzyme.
Another interesting class of inhibitors such as celgosivir, n-butyl deoxynojirimycin
and N-(n-nonyl) deoxynojirimycin
target host alpha-glucosidase enzyme and may offer alternative treatment options (131,132).
In substrate reduction therapy (SRT), the synthesis of glycosphingolipids is reduced by partial inhibition of glucosylceramide (G1cCer) synthase by deoxynojirimycin
analogs (5), leading to reduction of the glycosphingolipid pool and eventually to reduction of the substrate load for lysosomal degradation by sphingolipid hydrolases.
Quantitative determination of 1- deoxynojirimycin
in mulberry leaves using liquid chromatography-tandem mass spectrometry.
Glucosidase inhibitors such as deoxynojirimycin
(DNM) are reported to be potent antivirals and have been used in the treatment of an HIV infected lymphocyte culture, in which they inhibited the spread of the virus (Papandreou et al.